Related Experiment Video

Updated: Apr 19, 2026

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.7K

[MicroRNA and left ventricular hypertrophy]

Lian Duan, Xing-jiang Xiong, Yong-mei Liu

    Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica
    |December 20, 2014
    PubMed

    Insights

    MicroRNAs (miRNAs) regulate biological processes and are implicated in left ventricular hypertrophy (LVH), a complication of essential hypertension. Understanding miRNA roles offers potential for new diagnostic and therapeutic strategies.

    Area of Science:

    • Molecular Biology
    • Cardiovascular Research
    • Genetics

    Background:

    • MicroRNAs (miRNAs) are key regulators of gene expression involved in development and disease.
    • Essential hypertension is a major risk factor for cardiovascular diseases, with approximately one-third of patients developing left ventricular hypertrophy (LVH).
    • miRNAs play a critical role in the pathogenesis of LVH.

    Purpose of the Study:

    • To review the role of miRNAs in regulating stress signaling pathways relevant to LVH.
    • To define the impact of miRNAs on the development of LVH.
    • To explore the potential of miRNAs as biomarkers and therapeutic targets for LVH.

    Main Methods:

    • Literature review focusing on miRNA regulation of stress pathways.
    • Analysis of studies investigating miRNA involvement in LVH.
    • Evaluation of current research on miRNA-based diagnostics and therapeutics.

    Main Results:

    • miRNAs significantly influence the stress signaling pathways that contribute to LVH.
    • Specific miRNAs have been identified that promote or inhibit LVH development.
    • Dysregulation of certain miRNAs is associated with essential hypertension and LVH.

    Conclusions:

    • miRNAs are crucial regulators in the development of LVH associated with essential hypertension.
    • Targeting specific miRNAs presents a promising avenue for novel therapeutic interventions.
    • miRNAs hold potential as valuable biomarkers for early detection and risk stratification of LVH.

    More Related Videos

    Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy08:34

    Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

    Published on: September 25, 2017

    25.9K
    In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge09:53

    In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

    Published on: June 15, 2018

    8.0K

    Related Concept Videos

    Mitral Regurgitation I: Introduction01:20

    Mitral Regurgitation I: Introduction

    Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
    1.2K
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    812
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    1.6K
    Mitral Stenosis I: Introduction01:22

    Mitral Stenosis I: Introduction

    Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
    1.6K
    Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

    Mitral Regurgitation II: Clinical Features and Diagnostic Tests

    Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
    864
    Mitral Valve Prolapse I: Introduction01:27

    Mitral Valve Prolapse I: Introduction

    IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
    1.0K